A check up by Khosla Ventures determined that Docbot Inc. was healthy enough for the prominent biotech investor to take the lead in a $4 million series A round. The new funds bring the artificial intelligence company to a total of $8.5 million in capital raised to date. Other participants included Bold Capital Partners, Collaborative Fund and Boutique Venture Partners. Docbot's platform, Ultivision AI, uses artificial intelligence to enhance detection of gastrointestinal (GI) disease. The Irvine, Calif.-based company is targeting identification and classification of polyps, Barrett's esophagus, and ulcerative colitis to start.

Information contained on this page is provided by an independent third-party content provider. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com After months of interface development and testing at the University of California Irvine (UCI), Docbot, a medical informatics company, officially announced today its suite of artificial intelligence-driven applications for colonoscopy procedures. Collectively called Qualoscopy, the applications are designed to assist gastroenterologists in real-time. According to the Center for Disease Control, about 15 million colonoscopies were performed in the United States alone in 2012.